RecruitingPhase 3NCT06733129

Best Hypnotic Drug Choice for Rapid Sequence Induction in the Operating Room

Best Hypnotic Drug Choice for Rapid Sequence Induction in the Operating Room: a 3-arm Randomized Trial


Sponsor

Nantes University Hospital

Enrollment

1,218 participants

Start Date

Apr 14, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

The best hypnotic choice to optimize the balance between good intubation condition quality and hemodynamic stability during RSI performed in the operating theatre remained to be investigated. Therefore, a randomized study evaluating the efficacy of propofol, ketamine, and a combination of both is appropriate. So, we designed the HyPnotiKs randomized controlled study to investigate the efficacy of these hypnotic drugs in patients undergoing RSI in the operating theatre. The primary endpoint will be the successful tracheal intubation at the first attempt without major arterial hypotension event.


Eligibility

Min Age: 18 YearsMax Age: 80 Years

Inclusion Criteria10

  • age between 18 - 80 years' old
  • female\* and male
  • ≥ 1 risk factor of aspiration of gastric contents defined as
  • preoperative fasting period of less than 6 hours,
  • occlusive syndrome, functional ileus, vomiting episode within the last 12 hours,
  • orthopaedic trauma within the last 12 hours,
  • medical history of symptomatic gastroesophageal reflux or hiatus, hernia or gastroparesis or dysautonomia or gastroesophageal surgery with sphincter dysfunction)
  • patient requiring orotracheal intubation during general anaesthesia in the operating room.
  • patient or his/her next of kin written informed consent or emergency procedure
  • failure to discontinue GLP1 analogue as recommended (exenatide, liraglutide, albiglutide, taspoglutide, lixisenatide)

Exclusion Criteria12

  • predicted impossible tracheal intubation (≥ 1 of the following criteria: patient with known intubation complications, Mallampati score IV, Thyromental Distance ≤ 4.0 cm, Mouth Opening \< 3 cm, Sternomental Distance \< 12.5 cm, significant modification of the airway due to congenital, cancer, trauma or burning lesions (non-exhaustive list)) \[30\]
  • preoperative arterial hypotension (MAP \< 65 mmHg or under catecholamine)
  • preoperative respiratory distress syndrome (SpO2 \< 90% in room air)
  • contraindications to the use of ketamine and/or propofol and/or NMB:
  • allergy to the active substance or to one of the excipients or to soy or peanuts,
  • porphyria
  • intracranial hypertension
  • uncontrolled arterial hypertension (systolic arterial pressure \> 180 mmHg)
  • personal or family history of known malignant hyperthermia, congenital muscular dystrophy, myasthenia, a known congenital deficit in plasma pseudocholinesterase
  • pregnancy or breast-feeding woman
  • patients under court protection or guardianship
  • absence of insurance covering health costs

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGdirect IV injection

direct IV injection at dosage of 2 mg/kg (adjusted body weight if BMI \> 30) after completing pre-oxygenation

DRUGcombination of Ketamine and Propofol

combination of Ketamine and Propofol described above: consecutive direct IV injection of Ketamine 1 mg/kg and Propofol 1 mg/kg (adjusted body weight if BMI \> 30). Dilution are not necessary.


Locations(20)

Chr Angers

Angers, France

CHRU de Brest Hôpital Cavale Blanche

Brest, France

Ch Louis Pasteur

Chartres, France

CHU Dijon

Dijon, France

CHU Grenoble Alpes

Grenoble, France

CHD Vendée

La Roche-sur-Yon, France

APHP Bicêtre

Le Kremlin-Bicêtre, France

CH Le Mans

Le Mans, France

CHU Lille Hopital Salengro

Lille, France

CHU Lille Hôpital Claude Huriez

Lille, France

CHU Lyon Hôpital Sud

Lyon, France

HCL Lyon Croix-Rousse

Lyon, France

Chu Nantes (Laennec)

Nantes, France

Chu Nantes

Nantes, France

APHP St-Antoine

Paris, France

APHP Tenon

Paris, France

CHU Poitiers

Poitiers, France

Hopital Foch

Suresnes, France

CHU Toulouse Hôpital Purpan

Toulouse, France

CHU Toulouse Hôpital Rangueil

Toulouse, France

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06733129